Document Detail


Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study.
MedLine Citation:
PMID:  16565210     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The purpose of the study was to evaluate the outcome of Hodgkin's disease (HD) in patients infected with the human immunodeficiency virus (HIV) with respect to the use of highly active antiretroviral therapy (HAART). MATERIALS AND METHODS: This cohort study included patients with HIV-HD diagnosed from June 1984 to February 2004. Patients treated in the pre-HAART era (1984-1996) were compared with those belonging to the HAART era (1997-2004). RESULTS: Of 66 patients with HIV-HD, 47 (71%) presented with stage III/IV disease and 38 patients (58%) with an AIDS-defining illness. Fifty-nine of 66 patients (89.4%) underwent curative intended chemotherapy. Patients receiving HAART (n = 34) had a significantly better 2-year overall survival (OS) than those not receiving HAART (74% versus 30%, P <0.001). The 2-year OS of HAART-responders was 88% compared with 19% in patients without HAART-response (P = 0.0002). By multivariate analysis patients without HAART had a 5.6-fold higher risk for 3-year mortality [HR 5.6, 95% confidence interval (CI) 2.20-14.26]. Three-year mortality was significantly higher in patients without complete remission (HR 4.40, CI 1.77-10.99), with stage III/IV HD (HR 4.64, CI 1.31-16.49) and with CD4 cells <200/microl (HR 2.69, CI 0.99-7.33). CONCLUSIONS: Use of HAART significantly improved the overall survival in patients with HIV-HD.
Authors:
M Hentrich; L Maretta; K U Chow; J R Bogner; D Schürmann; P Neuhoff; H Jäger; D Reichelt; M Vogel; M Ruhnke; M Oette; R Weiss; J Rockstroh; K Arasteh; P Mitrou
Publication Detail:
Type:  In Vitro; Journal Article; Multicenter Study     Date:  2006-03-24
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  17     ISSN:  0923-7534     ISO Abbreviation:  Ann. Oncol.     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-05-18     Completed Date:  2006-11-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  914-9     Citation Subset:  IM    
Affiliation:
Department of Hematology/Oncology, Hospital Harlaching, Munich, Germany. tumorzentrum.hentrich@khmh.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acquired Immunodeficiency Syndrome / drug therapy*
Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Antiretroviral Therapy, Highly Active*
CD4 Lymphocyte Count
Cohort Studies
Disease-Free Survival
Female
Humans
Lymphoma, AIDS-Related / drug therapy*,  mortality*,  pathology
Multivariate Analysis
Neoplasm Staging
Patient Selection
Retrospective Studies
Survival Analysis
Time Factors
Viral Load

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Luminescence dating of the barrier spit at Chilika Lake, Orissa, India.
Next Document:  Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of...